As the medication becomes available, its impact on individuals suffering from obesity and related conditions is eagerly anticipated. However, the pricing challenges highlight the need ... Nov 17
The findings not only represent a major breakthrough for Eli Lilly but also for the scientific community as a whole, proving that perseverance and dedication ... Jul 18
Pharma merger and acquisitions... Jul 15
MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly's key therapeutic ... May 15
The move comes after the detection of different Covid variants ... Mar 26
The acquisition will establish a new modality for drug discovery and development at Lilly ... Dec 15
Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020... Nov 23
This collaboration will help to accelerate the work aimed to solve genetic diseases with unique editing challenges... Nov 21
Eli Lilly’s neutralizing antibody bamlanivimab receives US FDA emergency use authorization for the treatment of recently diagnosed COVID-19... Nov 12
WHO-led scheme to supply COVID-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead's GILD.... Nov 06
Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric ... Oct 28
Eli Lilly successfully develop and commercialize new medicines resulting from the acquisition... Oct 16
ELI Lilly, J & J and AstraZeneca halts covid drug trials... Oct 15
The survival rate is also relatively higher than other tumour types when having appropriate treatment... Oct 09
Drug combo cuts recurrence risk of breast cancer by 25%... Sep 21
Eli Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized Covid-19 patients. ... Sep 15
More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities;... Aug 03
ELI Lilly close to coronavirus antiviral as 3rd phase trial begins... Jun 17
This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera ... Jun 06
AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create ... Mar 13
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. With this ... Feb 22
Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin ... Sep 20
-Advertisements-
Saturday, December 02, 2023
